## News

### [Cyrus Biotechnology Announces Selection of CYR212 as Clinical Candidate for Chronic IgG-driven Autoimmune Disease Including Myasthenia Gravis and Immune Thrombocytopenia (Business Wire)](/content/cyrus-biotechnology-announces-selection-of-cyr212-as-clinical-candidate-for-chronic-igg-driven-autoimmune-disease-including-myasthenia-gravis-and-immune-thrombocytopenia-business-wire/index.html)

January 13, 2025

Article can be read via the following link: [Business Wire](https://www.businesswire.com/news/home/20250109147839/en/Cyrus-Biotechnology-Announces-Selection-of-CYR212-as-Clinical-Candidate-for-Chronic-IgG-driven-Autoimmune-Disease-Including-Myasthenia-Gravis-and-Immune-Thrombocytopenia)

### [Cyrus Biotechnology Spins out Levitate Bio, a Protein AI, Bioinformatics, and Rosetta Service Provider, to Bring Automated, Customized AI Solutions to Biopharma Drug Discovery](/content/cyrus-biotechnology-spins-out-levitate-bio-a-protein-ai-bioinformatics-and-rosetta-service-provider-to-bring-automated-customized-ai-solutions-to-biopharma-drug-discovery/index.html)

December 13, 2024

[Business Wire](https://www.businesswire.com/news/home/20240611967134/en/Cyrus-Biotechnology-Spins-out-Levitate-Bio-a-Protein-AI-Bioinformatics-and-Rosetta-Service-Provider-to-Bring-Automated-Customized-AI-Solutions-to-Biopharma-Drug-Discovery)

### [Cyrus Biotechnology Announces Potent in vivo Redosability of an Engineered IdeS Protease for IgG-driven Autoimmune Disease, Demonstrating No Anti-drug Antibodies (Business Wire)](/content/cyrus-biotechnology-announces-potent-in-vivo-redosability-of-an-engineered-ides-protease-for-igg-driven-autoimmune-disease-demonstrating-no-anti-drug-antibodies-business-wire/index.html)

December 11, 2024

Read article at the link below: [Business Wire](https://www.businesswire.com/news/home/20241211633894/en/Cyrus-Biotechnology-Announces-Potent-in-vivo-Redosability-of-an-Engineered-IdeS-Protease-for-IgG-driven-Autoimmune-Disease-Demonstrating-No-Anti-drug-Antibodies)

### [Cyrus Biotechnology to Present its Protein Engineering Capability, Immunogenicity Risk Mitigation, and Best-in-Class IgG Protease Candidate at Hit ID Summit (Business Wire)](/content/cyrus-biotechnology-to-present-its-protein-engineering-capability-immunogenicity-risk-mitigation-and-best-in-class-igg-protease-candidate-at-hit-id-summit-business-wire/index.html)

November 12, 2024

Cyrus CSO and co-founder Yifan Song performed a presentation at the Hit ID Summit in Boston, speaking on a few topics including Cyrus’ hybrid AI/screening platform in risk mitigation of protein therapeutics.

### [Cyrus Biotechnology Congratulate Co-Founder David Baker on 2024 Nobel Prize in Chemistry (Business Wire)](/content/cyrus-biotechnology-congratulate-co-founder-david-baker-on-2024-nobel-prize-in-chemistry-business-wire/index.html)

October 11, 2024

Cyrus co-founder and Computational Biologist David Baker was recently awarded as a 2024 Nobel Laureate in Chemistry. Congratulations to David on receiving such a prestigious honor. Here is the link to the article: [Business Wire](https://www.businesswire.com/news/home/20241011/en/Cyrus-Biotechnology-Congratulate-Co-Founder-David-Baker-on-2024-Nobel-Prize-in-Chemistry)

### [Cyrus Biotechnology to Present Its Novel IgG-degrading IdeS Enzyme Development Candidates for Autoimmune Indications at PepTalk Conference in San Diego](/content/cyrus-biotechnology-to-present-its-novel-igg-degrading-ides-enzyme-development-candidates-for-autoimmune-indications-at-peptalk-conference-in-san-diego/index.html)

January 17, 2024

Director of Discovery Dr. Erik Procko recently performed a presentation on Cyrus’ novel IgG-degrading IdeS enzyme development candidates at PepTalk Conference San Diego on January 16th. The article can be found via: [Cyrus Website](/content/cyrus-biotechnology-to-present-its-novel-igg-degrading-ides-enzyme-development-candidates-for-autoimmune-indications-at-peptalk-conference-in-san-diego/index.html)